｜NIPH Clinical Trials Search

UMIN ID: UMIN000054659

Registered date:14/06/2024

Immune checkpoint inhibitors for neoadjuvant chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis

Basic Information

Recruitment status	Pending
Health condition(s) or Problem(s) studied	non-small cell lung cancer
Date of first enrollment	2024/06/13
Target sample size
Countries of recruitment	Japan
Study type	Others,meta-analysis etc
Intervention(s)

TO Original Data: UMIN

Outcome(s)

Primary Outcome	The co-primary outcomes of this analysis will be the hazard ratio (HR) for overall survival (HRos) and, the HR for event-free survival (EFS, HRefs). Although progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) are not identical to EFS, these outcomes will be analyzed collectively due to their conceptual similarity, especially for patients with successful surgical removal. Additionally, the odds ratio (OR) for surgical resection rate, complete surgical removal of a tumor with no visible or microscopic cancer cells left at the margins of the resected tissue (R0 resection), major pathological response (MPR), any grade treatment-related adverse event (any TRAE), grade 3 or higher TRAE (>= G3 TRAE), grade 5 AE, serious AE, and AE leading to surgery cancellation will also be analyzed.
Secondary Outcome

Primary Outcome

The co-primary outcomes of this analysis will be the hazard ratio (HR) for overall survival (HRos) and, the HR for event-free survival (EFS, HRefs). Although progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) are not identical to EFS, these outcomes will be analyzed collectively due to their conceptual similarity, especially for patients with successful surgical removal. Additionally, the odds ratio (OR) for surgical resection rate, complete surgical removal of a tumor with no visible or microscopic cancer cells left at the margins of the resected tissue (R0 resection), major pathological response (MPR), any grade treatment-related adverse event (any TRAE), grade 3 or higher TRAE (>= G3 TRAE), grade 5 AE, serious AE, and AE leading to surgery cancellation will also be analyzed.

Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	None

Related Information

Primary Sponsor	Yokohama City University Hospital
Secondary Sponsor
Source(s) of Monetary Support	Other
Secondary ID(s)

Contact

public contact
Name	Nobuyuki Horita
Address	3-9, Fukuura, Kanazawa, Yokohama, Japan Japan 236-0004
Telephone	045-787-2800
E-mail	horitano@yokohama-cu.ac.jp
Affiliation	Yokohama City University Hospital Chemotherapy Center
scientific contact
Name	Nobuyuki Horita
Address	3-9, Fukuura, Kanazawa, Yokohama, Japan Japan
Telephone	045-787-2800
E-mail	horitano@yokohama-cu.ac.jp
Affiliation	Yokohama City University Hospital Chemotherapy Center

TO Original Data: UMIN